Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Company's first biologic license application (BLA) candidate TTAX01 to enter Investigational New Drug (IND) Phase 3 Trials for Diabetic Foot Ulcer (DFU) indication as first biologic product to seek FDA approval for complex Wagner Grade 3 and 4 DFUs .
Brand Name : TTAX01
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 30, 2020
LOOKING FOR A SUPPLIER?
Reset All
